Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 8,000 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $13.79, for a total value of $110,320.00. Following the completion of the transaction, the chief executive officer now owns 1,080,536 shares in the company, valued at $14,900,591.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Tarsus Pharmaceuticals Stock Down 5.0 %

Shares of Tarsus Pharmaceuticals stock traded down $0.67 during midday trading on Friday, hitting $12.75. The company’s stock had a trading volume of 247,899 shares, compared to its average volume of 74,542. The firm has a market capitalization of $340.04 million, a P/E ratio of -5.00 and a beta of 0.69. The stock has a 50-day simple moving average of $15.07 and a 200-day simple moving average of $15.87. The company has a quick ratio of 16.40, a current ratio of 16.40 and a debt-to-equity ratio of 0.10. Tarsus Pharmaceuticals, Inc. has a 1-year low of $10.80 and a 1-year high of $19.66.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG boosted its position in shares of Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after buying an additional 1,142 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter worth $94,000. Legal & General Group Plc boosted its position in shares of Tarsus Pharmaceuticals by 182.9% in the fourth quarter. Legal & General Group Plc now owns 6,903 shares of the company’s stock worth $101,000 after buying an additional 4,463 shares during the period. Barclays PLC boosted its position in shares of Tarsus Pharmaceuticals by 110.5% in the fourth quarter. Barclays PLC now owns 7,918 shares of the company’s stock worth $116,000 after buying an additional 4,157 shares during the period. Finally, American International Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 102.7% in the second quarter. American International Group Inc. now owns 8,486 shares of the company’s stock worth $124,000 after buying an additional 4,300 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Tarsus Pharmaceuticals

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.